We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > thyroid eye disease

News List

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease prnasia
October 20, 2021
Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in phase II trial for the treatment of thyroid eye disease (TED).
FDA Advisory Committee votes unanimously to support use of teprotumumab to treat thyroid eye disease pharmaceutical-business-review
December 20, 2019
Horizon Therapeutics announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the US Food and Drug Administration (FDA) voted unanimously ...